LOGIN
AAHKS 2023: Extended- Vs Immediate-Release Triamcinolone Acetonide for Osteoarthritis
November 2023
AAHKS 2023: Extended- Vs Immediate-Release Triamcinolone Acetonide for Osteoarthritis
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Extended-Versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis With Comorbid Diabetes
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
Patients with knee osteoarthritis with comorbid type 2 diabetes mellitus were randomized to receive either intra-articular extended-release triamcinolone acetonide (IA TA-ER) or immediate-release triamcinolone acetonide (TA-IR). Blood glucose levels (BGLs), glycemic variability, percentage of time in target range, percentage of time above range, and changes from baseline in daily average BGL were ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.